The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The top public health officials during Trump's first term praised mRNA vaccines. In the second term, officials seem to be ...

They’re turning their backs on a technology thought to have saved millions of lives—with the potential to save many more.

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The HHS secretary recently canceled $500 million worth of BARDA contracts around mRNA vaccine research. But the U.S.

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...